Kiniksa Pharmaceuticals International (KNSA) earnings

Earnings (net income) · fiscal 2025
$59.01M

Kiniksa Pharmaceuticals International (KNSA) reported net income of $59.01M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$43.19M. Figures as of 18 Nov 2026, 05:39 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings (net income), fiscal 2025
$59.01M
Highest on record
$183.36Mfiscal 2022
Lowest on record
-$161.87Mfiscal 2019
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kiniksa Pharmaceuticals International earnings, in more detail

Across the 9 fiscal years on record (2017–2025), the highest was $183.36M in fiscal 2022 and the lowest -$161.87M in fiscal 2019.

History · 9 fiscal years

Earnings (net income) by fiscal year

Kiniksa Pharmaceuticals International earnings, year by year

Kiniksa Pharmaceuticals International (KNSA) earnings by fiscal year
Fiscal yearEarnings (net income)ChangeYear ended
2025$59.01M—
2024-$43.19M 406.7% down
2023$14.08M 92.3% down
2022$183.36M—
2021-$157.92M—
2020-$161.38M—
2019-$161.87M—
2018-$103.23M—
2017-$64.87M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

Earnings (net income) at health care companies of similar size

Earnings (net income) of Kiniksa Pharmaceuticals International and comparable companies
CompanyEarnings (net income)Fiscal year
Alkermes ALKS$241.66M2025
PACS Group PACS$191.54M2025
Kiniksa Pharmaceuticals International KNSA$59.01M2025
ImmunityBio IBRX-$351.40M2025
Cytokinetics CYTK-$784.96M2025
ABIVAX ABVX-€336.10M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KNSA

Kiniksa Pharmaceuticals International, figure by figure

Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value

Kiniksa Pharmaceuticals International earnings: questions and answers

What is Kiniksa Pharmaceuticals International's net income?

Kiniksa Pharmaceuticals International (KNSA) reported net income of $59.01M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$43.19M.

What are the highest and lowest net income figures on record for Kiniksa Pharmaceuticals International?

Across the 9 fiscal years on record (2017–2025), the highest was $183.36M in fiscal 2022 and the lowest -$161.87M in fiscal 2019.

How is Kiniksa Pharmaceuticals International's net income calculated?

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/KNSA/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.